COMMUNIQUÉS West-GlobeNewswire

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

13/03/2025 - 21:01

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025 In parallel, the Company continues to analyze data and explore opportunities for LYR-210 in CRS [...]

Senti Bio Appoints Feng Hsiung to Board of Directors

13/03/2025 - 21:01

– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a [...]

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

13/03/2025 - 21:01

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable [...]

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

13/03/2025 - 21:02

Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial [...]

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

13/03/2025 - 21:02

Q4 2024 revenue increased 24.6% over Q3 2024 ; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 [...]

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

13/03/2025 - 21:05

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining [...]

The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results

13/03/2025 - 21:05

- Grew revenue from continuing operations 10% annually and 14% quarterly compared to the same period in 2023 - - Increased system-wide sales 9% for both the year and Q4 2024 – SCOTTSDALE, Ariz., March 13, 2025 (GLOBE [...]

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

13/03/2025 - 21:05

– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs [...]

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

13/03/2025 - 21:05

- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million [...]

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

13/03/2025 - 21:05

Conference Call and Live Audio Webcast Scheduled for March 20, 2025 PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates [...]

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

13/03/2025 - 21:07

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable [...]

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

13/03/2025 - 21:10

GAITHERSBURG, Md., March 13, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

13/03/2025 - 21:15

Southlake, TX, March 13, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , an artificial intelligence (“AI”)-powered medical technology company focused on [...]

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

13/03/2025 - 21:15

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancer Recently announced positive final data from [...]

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

13/03/2025 - 21:30

SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, [...]

MEDIROM Mother Labs Executive Makes Additional Investment in Mother Labs’ Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of March 13, 2025, Approximately US$60 Million)

13/03/2025 - 22:00

TOKYO, March 13, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that Yasuhiro Hayami, Chief Business Officer of MEDIROM Mother Labs Inc. (“Mother Labs [...]

Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference

13/03/2025 - 22:00

PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and [...]

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

13/03/2025 - 22:00

MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of [...]

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social

13/03/2025 - 22:15

Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 mars 2025 (GLOBE NEWSWIRE) -- Paris, France, le 13 mars 2025 Place de cotation : [...]